CA3124220A1 - Substituted oxopyridine derivatives - Google Patents
Substituted oxopyridine derivatives Download PDFInfo
- Publication number
- CA3124220A1 CA3124220A1 CA3124220A CA3124220A CA3124220A1 CA 3124220 A1 CA3124220 A1 CA 3124220A1 CA 3124220 A CA3124220 A CA 3124220A CA 3124220 A CA3124220 A CA 3124220A CA 3124220 A1 CA3124220 A1 CA 3124220A1
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- methyl
- mixture
- represents hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 | ||
| CNPCT/CN2018/122825 | 2018-12-21 | ||
| PCT/EP2019/085983 WO2020127504A1 (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3124220A1 true CA3124220A1 (en) | 2020-06-25 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3124220A Pending CA3124220A1 (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (pt) |
| JP (1) | JP2022514303A (pt) |
| KR (1) | KR20210106504A (pt) |
| CN (1) | CN113474348A (pt) |
| AR (1) | AR117435A1 (pt) |
| AU (1) | AU2019407909B2 (pt) |
| BR (1) | BR112021009435A2 (pt) |
| CA (1) | CA3124220A1 (pt) |
| CL (1) | CL2021001613A1 (pt) |
| CO (1) | CO2021007908A2 (pt) |
| CR (1) | CR20210342A (pt) |
| DO (1) | DOP2021000128A (pt) |
| EA (1) | EA202191764A1 (pt) |
| EC (1) | ECSP21043895A (pt) |
| IL (1) | IL283990A (pt) |
| JO (1) | JOP20210161A1 (pt) |
| MA (1) | MA54521A (pt) |
| MX (1) | MX2021007508A (pt) |
| PE (1) | PE20211790A1 (pt) |
| SG (1) | SG11202104384PA (pt) |
| TW (1) | TW202039510A (pt) |
| WO (1) | WO2020127504A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200232B1 (ar) * | 2018-03-15 | 2023-09-17 | Bayer Ag | عملية لتحضير اثنين من مشتقات 4-{[(2s)-2-{4-[5-كلورو-2-(1h-1، 2، 3-تريازول-1-يل) فنيل]-5-مثوكسي-2-أوكسوبيريدين-1(2h)-يل} بيوتانويل] أمينو}-2-فلوروبنزاميد |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| KR20230155505A (ko) | 2021-03-09 | 2023-11-10 | 바이엘 악티엔게젤샤프트 | (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로-메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-5 디벤제나헵타판-74-카르복스아미드의 결정질 형태 |
| KR20230155504A (ko) | 2021-03-09 | 2023-11-10 | 바이엘 악티엔게젤샤프트 | (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-디벤제나헵타판-74-카르복스아미드를 포함하는 제약 투여 형태 |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| CA2918814C (en) | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| ES2659045T3 (es) | 2013-10-30 | 2018-03-13 | Bayer Pharma Aktiengesellschaft | Derivados de oxopiridina sustituidos |
| ES2694189T3 (es) | 2014-09-24 | 2018-12-18 | Bayer Pharma Aktiengesellschaft | Derivados de oxopiridina sustituidos |
| CA2961981A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2712886T3 (es) | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| ES2716417T3 (es) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
| WO2016046166A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| ES2722423T3 (es) | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| EP3271332A1 (de) | 2015-03-19 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| EP3344618A1 (de) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
-
2019
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en unknown
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en active Active
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021007908A2 (es) | 2021-07-19 |
| DOP2021000128A (es) | 2021-09-30 |
| MX2021007508A (es) | 2021-08-05 |
| MA54521A (fr) | 2022-03-30 |
| CL2021001613A1 (es) | 2021-12-03 |
| BR112021009435A2 (pt) | 2021-08-17 |
| EA202191764A1 (ru) | 2021-10-22 |
| TW202039510A (zh) | 2020-11-01 |
| ECSP21043895A (es) | 2021-07-30 |
| AU2019407909B2 (en) | 2023-05-25 |
| PE20211790A1 (es) | 2021-09-09 |
| EP3898633A1 (en) | 2021-10-27 |
| CR20210342A (es) | 2021-08-09 |
| CN113474348A (zh) | 2021-10-01 |
| JP2022514303A (ja) | 2022-02-10 |
| JOP20210161A1 (ar) | 2023-01-30 |
| AR117435A1 (es) | 2021-08-04 |
| KR20210106504A (ko) | 2021-08-30 |
| AU2019407909A1 (en) | 2021-05-27 |
| IL283990A (en) | 2021-07-29 |
| WO2020127504A1 (en) | 2020-06-25 |
| SG11202104384PA (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019407909B2 (en) | Substituted oxopyridine derivatives | |
| US9765070B2 (en) | Substituted oxopyridine derivatives | |
| CN108026072B (zh) | 取代的氧代吡啶衍生物 | |
| AU2014242971B2 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
| US10138236B2 (en) | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | |
| CN106687458B (zh) | 取代的氧代吡啶衍生物 | |
| US10414731B2 (en) | Substituted oxopyridine derivatives | |
| US20180250280A1 (en) | Substituted oxopyridine derivatives | |
| CA2979937A1 (en) | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis | |
| CA3123324A1 (en) | Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications | |
| US10077265B2 (en) | Substituted oxopyridine derivatives | |
| TW201808908A (zh) | 因子XIa抑制劑 | |
| CA3124296A1 (en) | Substituted oxopyridine derivatives | |
| JP2016520113A (ja) | 血栓塞栓疾患の治療のためのトロンビン阻害薬としてのトリアゾロピリジン類 | |
| EA044932B1 (ru) | Замещенные оксопиридиновые производные | |
| JP2016520111A (ja) | 置換ベンゾキサゾール | |
| JP2016520110A (ja) | 置換ベンゾキサゾール | |
| TW202320754A (zh) | 經取代的ｓ－丙胺酸酯衍生物 | |
| JP2008512365A (ja) | 第Ｘａ因子阻害物質として使用する、Ｎ−（１−（２，３−ジヒドロ−１Ｈ−インデン−５イル）−２−オキソ−３−ピロリジニル）−スルホンアミド誘導体 |